Media coverage
2
Media coverage
Title AbbVie Receives U.S. FDA Approval of MAVYRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks; - MAVYRET is a new 8-week, pan-genotypic treatment for hepatitis C patients withou Media name/outlet PR Newswire Country United States Date 8/3/17 Persons Fred Poordad Title AbbVie Receives U.S. FDA Approval of MAVYRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks; - MAVYRET is a new 8-week, pan-genotypic treatment for hepatitis C patients withou Media name/outlet PR Newswire Country United States Date 8/3/17 Persons Fred Poordad